Cell lines are established by isolating cells from a tissue source and culturing them under conditions that support repeated division over many generations, producing a consistent, renewable population for laboratory and manufacturing use.
In the manufacture of some extracellular vesicle and exosome products, a characterized cell line serves as the source cell population cultured to generate conditioned medium, from which vesicles are later isolated and concentrated. Bio Xsomes, for example, is derived from an hPESC progenitor endothelial cell line; request source and processing documentation for the specific product.
FDA has stated that no exosome products are currently FDA-approved. These products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, and purchase and clinical-use decisions belong to the physician together with their own regulatory counsel.
A buyer evaluating a cell line-derived product can request documentation of the source cell line's origin and characterization, separate from any claims about the finished product's composition, which should be supported by its own lot-specific certificate of analysis.
Knowing whether a finished product is tissue-derived or cell line-derived helps buyers ask the right manufacturing and documentation questions.